Literature DB >> 15289295

Expression of matrix metalloproteinase-9 in human platelets: regulation of platelet activation in in vitro and in vivo studies.

Joen R Sheu1, Tsorng H Fong, Cheng M Liu, Ming Y Shen, Ta L Chen, Yi Chang, Meng S Lu, George Hsiao.   

Abstract

1. The aim of this study was to identify the presence of matrix metalloproteinase-9 (MMP-9) in human platelets and systematically examine its inhibitory mechanisms of platelet activation. 2. In this study, we report on an efficient method for the quantitative analysis of pro-MMP-9 in human platelets using capillary zone electrophoresis (CZE). To elucidate subcellular localization of MMP-9 in human platelets, we investigated intraplatelet MMP-9 by immunogold labeling and visualized it using electron microscopy. In an in vivo thrombotic study, platelet thrombus formation was induced by irradiation of mesenteric venules with filtered light in mice pretreated with fluorescein sodium. 3. MMP-9-gold labeling was observed on the plasma membrane, alpha-granules, open canalicular system, and within the cytoplasma both in resting and activated platelets. Furthermore, activated MMP-9 concentration-dependently (15-90 ng ml(-1)) inhibited platelet aggregation stimulated by agonists. Activated MMP-9 (21 and 90 ng ml(-1)) inhibited phosphoinositide breakdown, intracellular Ca(2+) mobilization, and thromboxane A(2) formation in human platelets stimulated by collagen (1 microg ml(-1)). In addition, activated MMP-9 (21 and 90 ng ml(-1)) significantly increased the formation of nitric oxide/cyclic GMP. 4. Rapid phosphorylation of a platelet protein of Mr 47,000 (P47), a marker of protein kinase C activation, was triggered by phorbol-12, 13-dibutyrate (PDBu) (60 nm). This phosphorylation was markedly inhibited by activated MMP-9 (21 and 90 ng ml(-1)). Activated MMP-9 (1 microg g(-1)) significantly prolonged the latency period of inducing platelet plug formation in mesenteric venules. 5. These results indicate that the antiplatelet activity of activated MMP-9 may be involved in the following pathways. (1) Activated MMP-9 may inhibit the activation of phospholipase C, followed by inhibition of phosphoinositide breakdown, protein kinase C activation, and thromboxane A(2) formation, thereby leading to inhibition of intracellular Ca(2+) mobilization. (2) Activated MMP-9 also activated the formation of nitric oxide/cyclic GMP, resulting in inhibition of platelet aggregation. These results strongly indicate that MMP-9 is a potent inhibitor of aggregation. It may play an important role as a negative feedback regulator during platelet activation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15289295      PMCID: PMC1575278          DOI: 10.1038/sj.bjp.0705917

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  26 in total

1.  Human fibroblast stromelysin catalytic domain: expression, purification, and characterization of a C-terminally truncated form.

Authors:  A I Marcy; L L Eiberger; R Harrison; H K Chan; N I Hutchinson; W K Hagmann; P M Cameron; D A Boulton; J D Hermes
Journal:  Biochemistry       Date:  1991-07-02       Impact factor: 3.162

Review 2.  The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis.

Authors:  J M Ray; W G Stetler-Stevenson
Journal:  Eur Respir J       Date:  1994-11       Impact factor: 16.671

3.  Platelet aggregation induced by alpha 2-adrenoceptor and protein kinase C activation. A novel synergism.

Authors:  W Siess; E G Lapetina
Journal:  Biochem J       Date:  1989-10-15       Impact factor: 3.857

Review 4.  Matrix metalloproteinases and cardiovascular disease.

Authors:  C M Dollery; J R McEwan; A M Henney
Journal:  Circ Res       Date:  1995-11       Impact factor: 17.367

Review 5.  Proteolytic remodeling of extracellular matrix.

Authors:  H Birkedal-Hansen
Journal:  Curr Opin Cell Biol       Date:  1995-10       Impact factor: 8.382

6.  In vivo antithrombotic effect of triflavin, an Arg-Gly-Asp containing peptide on platelet plug formation in mesenteric microvessels of mice.

Authors:  J R Sheu; S H Chao; M H Yen; T F Huang
Journal:  Thromb Haemost       Date:  1994-10       Impact factor: 5.249

7.  Phorbol esters increase the amount of Ca2+, phospholipid-dependent protein kinase associated with plasma membrane.

Authors:  A S Kraft; W B Anderson
Journal:  Nature       Date:  1983 Feb 17-23       Impact factor: 49.962

8.  Identification and functional characterization of protein kinase C isozymes in platelets and HEL cells.

Authors:  J Grabarek; M Raychowdhury; K Ravid; K C Kent; P J Newman; J A Ware
Journal:  J Biol Chem       Date:  1992-05-15       Impact factor: 5.157

9.  Inhibition of nitric oxide biosynthesis promotes P-selectin expression in platelets. Role of protein kinase C.

Authors:  T Murohara; S J Parkinson; S A Waldman; A M Lefer
Journal:  Arterioscler Thromb Vasc Biol       Date:  1995-11       Impact factor: 8.311

10.  Rapid accumulation of inositol trisphosphate reveals that agonists hydrolyse polyphosphoinositides instead of phosphatidylinositol.

Authors:  M J Berridge
Journal:  Biochem J       Date:  1983-06-15       Impact factor: 3.857

View more
  25 in total

1.  Nanoparticle-induced platelet aggregation and vascular thrombosis.

Authors:  Anna Radomski; Paul Jurasz; David Alonso-Escolano; Magdalena Drews; Maria Morandi; Tadeusz Malinski; Marek W Radomski
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

2.  The platelet phenotype in patients with ST-segment elevation myocardial infarction is different from non-ST-segment elevation myocardial infarction.

Authors:  Rachel A Schmidt; Craig N Morrell; Frederick S Ling; Preya Simlote; Genaro Fernandez; David Q Rich; David Adler; Joe Gervase; Scott J Cameron
Journal:  Transl Res       Date:  2017-12-02       Impact factor: 7.012

Review 3.  Use of electron microscopy to study platelets and thrombi.

Authors:  Maurizio Tomaiuolo; Rustem I Litvinov; John W Weisel; Timothy J Stalker
Journal:  Platelets       Date:  2020-05-18       Impact factor: 3.862

4.  FlnA-null megakaryocytes prematurely release large and fragile platelets that circulate poorly.

Authors:  Antonija Jurak Begonja; Karin M Hoffmeister; John H Hartwig; Hervé Falet
Journal:  Blood       Date:  2011-06-07       Impact factor: 22.113

5.  Megakaryocytes differentially sort mRNAs for matrix metalloproteinases and their inhibitors into platelets: a mechanism for regulating synthetic events.

Authors:  Luca Cecchetti; Neal D Tolley; Noemi Michetti; Loredana Bury; Andrew S Weyrich; Paolo Gresele
Journal:  Blood       Date:  2011-05-31       Impact factor: 22.113

6.  The Sample Type used Affects the Levels of Gelatinases (MMP-2 and -9) and their Inhibitors (TIMP-1 and -2) in Circulating Blood of Healthy Controls and Breast Cancer Patients.

Authors:  Kuvaja Paula; Talvensaari-Mattila Anne; Turpeenniemi-Hujanen Taina
Journal:  Biomark Insights       Date:  2007-04-03

7.  Activated tumor cell integrin αvβ3 cooperates with platelets to promote extravasation and metastasis from the blood stream.

Authors:  Martin R Weber; Masahiko Zuka; Mihaela Lorger; Mario Tschan; Bruce E Torbett; Andries Zijlstra; James P Quigley; Karin Staflin; Brian P Eliceiri; Joseph S Krueger; Patrizia Marchese; Zaverio M Ruggeri; Brunhilde H Felding
Journal:  Thromb Res       Date:  2016-04       Impact factor: 3.944

8.  Phenotypic heterogeneity in the Gray platelet syndrome extends to the expression of TREM family member, TLT-1.

Authors:  Alan T Nurden; Paquita Nurden; Emilsé Bermejo; Robert Combrié; Daniel W McVicar; A Valance Washington
Journal:  Thromb Haemost       Date:  2008-07       Impact factor: 5.249

9.  Differential MMP-9 activity in CD34⁺progenitor cell-derived foam cells from diabetic and normoglycemic patients.

Authors:  J U Schmohl; K Daub; S N I von Ungern-Sternberg; S Lindemann; T Schönberger; T Geisler; M Gawaz; P Seizer
Journal:  Herz       Date:  2013-12-05       Impact factor: 1.443

10.  Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis.

Authors:  Leonardo Lorente; María M Martín; Lorenzo Labarta; César Díaz; Jordi Solé-Violán; José Blanquer; Josune Orbe; José A Rodríguez; Alejandro Jiménez; Juan M Borreguero-León; Felipe Belmonte; Juan C Medina; Maria C Llimiñana; José M Ferrer-Agüero; José Ferreres; María L Mora; Santiago Lubillo; Manuel Sánchez; Ysamar Barrios; Antonio Sierra; José A Páramo
Journal:  Crit Care       Date:  2009-10-02       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.